The growth of interest in the biology of lung cancer is a welcome product of frustration with the results of current treatment. The last 15 years have seen a considerable increase in our knowledge of the disease, and we can but hope that therapeutic advances will result. It is the most common cause of death from cancer in men, and in the United States in the last two years it has overtaken breast cancer as the most common cause of fatal cancer in women. An additional spur to biological investigation has been the recognition of four pathological types of the disease. There is growing acceptance of the hypothesis that lung cancer starts in a cell capable of differentiating into various pathological forms (fig 1) . This is supported by the occurrence of mixed pathological types (for example, mixed squamous and small cell). In cell lines and in biopsy material it has been shown that neuroendocrine features, typical of small cell lung cancer, can be found in adenocarcinoma and that cytokeratins, which are uniformly found in squamous cell carcinomas, are expressed in small cell lung cancer.
Small cell lung cancer shows the typical pathological features of neuroendocrine differentiation: neurosecretory dense core granules, chromogranin A, cytoplasmic L dopa decarboxylase, the glycolytic enzyme neurone specific enolase, and production of hormones and neuropeptides. There is some evidence that when some of these features are detected in any adenocarcinoma this is more likely to respond to chemotherapy,' though more recent studies have indicated that the effect is small. 3) . Proteins such as collagen, fibronectin, lamina, and tenascin are essential components of the extracellular matrix. Integrins are heterodimeric transmembrane receptor proteins that bind to laminin, collagen, and fibronectin. In doing so they link the cytoskeleton of the cell with the matrix.9 The integrin family is a complex in which the a chain varies and the f peptide defines the class. The variety ofintegrin expression is apparently reduced in cancer. Integrins appear in a later stage ofcellular differentiation and are found on squamous cancers. Glycolipid antigens (GD2 and GD3) are also expressed in lung cancer and may be important in cell invasion in this and other tumours.'0
ANTIGENS THAT ARE RECEPTORS CONCERNED WITH TRANSMEMBRANE SIGNAL INDUCTION
The cell membrane contains a range of receptors for growth factors, cytokines, and toxins as well as proteins concerned with drug attachment and efflux. Figure 4 shows some of these proteins and indicates some of the diversity of function. The epidermal growth factor receptor is expressed on non-small cell lung cancers" and receptors for insulin like growth factors on small cell lung cancers. These receptors and others, such as those for platelet derived growth factor, are widely distributed on tumours and normal cells. Of particular interest in small cell lung cancer is the expression of receptors for growth inducing peptides, such as gastrin releasing peptide (bombesin), which are secreted by the tumour and which, on becoming bound to the tumour cell, promote cell division-that is, autocrine growth stimulation.
Other membrane associated proteins concern cellular functions of detoxification and cation transport. The p170 glycoprotein is associated with cellular resistance to the effects of naturally occurring antitumour substances, such as doxorubicin, epipodophyllotoxin, and colchicine. The protein acts as a drug efflux mechanism and methods to circumvent its action may yet give useful therapeutic results. -O Figure 5 Potential mechanisms for tumour cell killing by mohoclonal reagents. 1: toxin is coupled to antibody that is internalised, resulting in toxin mediated cell dea 2: the antibody acts as a bridge to a cytolytic effector cell; 3: the antibody induces complement mediated lysis; 4: the antibody is conjugated to a radionuclide that irradiates the tumour; 5: the antibody is conjugated to an enzyme that activates an prodrug in the region of the tumour (or normal tissue).
transiently during tissue development and are re-expressed in neoplasia. Some of these carbohydrate antigens are also found on glycoproteins, such as mucins or adhesion molecules, and the patterns of glycosylation in these high molecular weight structures may be different in normal and malignant cells. Blood group and glycolipid antigens are expressed on both small cell and non-small cell lung cancers. '2 Membrane receptors taking part in the transport of calcium, iron, copper, and other cations are found on the surface of lung cancer cells (and other tumour cells) as on normal cells and other tumours. Up regulation or altered expression of these receptors has not yet been described in lung cancer.
Lung cancer antigen workshops Two recent workshops3 14 have been undertaken to attempt to introduce a taxonomic description of the antigens being recognised by the numerous monoclonal antibodies to lung cancer cells. A summary ofthe major clusters of reactivity is given in the 
